



Once you find it, her treatment can be clear




The first and only therapy specifically for aBC patients with a PIK3CA mutation
aBC=advanced breast cancer.

Dear Dr.

PIQRAY nearly doubled mPFS in HR+/HER2- aBC patients with a PIK3CA mutation^{1,2}

Yours sincerely

Nearly doubled mPFS in patients with a PIK3CA mutation^{1,2}



Rapid separation of PFS curve evident at 2 months^{1,2}

Results reported at 2 months were not prespecified and are observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error

SOLAR-1 is the first phase 3 trial leading to approval of PIQRAY for aBC patients with a PIK3CA mutation^{1,2}

- Randomized, double-blind, placebo-controlled, multicenter phase 3 trial in HR+/HER2- aBC
- A total of 572 patients were enrolled in the trial, including 341 patients with a PIK3CA mutation

Consistent PFS results across different subgroups^{1,2}

PFS by Line of Therapy in the PIK3CA-mutant Cohort³

- mPFS was 11 months for PIQRAY + fulvestrant vs 6.8 months for Placebo + fulvestrant in first line therapy patients (HR = 0.71; [95% CI, 0.49-1.03])³
- mPFS was 10.9 months for PIQRAY + fulvestrant vs 3.7 months for Placebo + fulvestrant in second line therapy patients (HR = 0.61; [95% CI, 0.42-0.89])³

HR+/HER2- = hormone receptor positive/human epidermal growth factor receptor 2 negative; PIK3CA = Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; aBC = advanced breast cancer; MBC = Metastatic breast cancer; mPFS = median progression-free survival; HR = hazard ratio; CI = confidence interval

References: **1.** Piqray® (alpelisib) Core Data Sheet: Version 1.0. Novartis Pharma AG; November 2018. **2.** André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptorpositive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940. **3.** Juric D, Ciruelos EM, Rubovszky G, et al. Alpelisib (ALP) + Fulvestrant (FUL) for Advanced Breast Cancer (ABC): Phase 3 SOLAR-1 Trial Results. Presented at: San Antonio Breast Cancer Symposium, December 4-8, 2018.

DO YOU FIND THESE INFORMATION VALUABLE?



NSS

PATIENT SAFETY TEAM
CONTACT DETAILS